Proactive Investors - Run By Investors For Investors

AstraZeneca partner gets approval to market its roxadustat drug as an anaemia treatment in China

The FTSE 100-listed drugmaker said its partner FibroGen China received marketing authorisation from the Chinese National Medical Products Administration for orally-administered roxadustat
China
AstraZeneca said it and FibroGen expects to launch roxadustat in China in the second half of 2019

AstraZeneca PLC (LON:AZN.LN) has got approval in China to market its roxadustat drug as a treatment for patients with anaemia who have chronic kidney disease and are on dialysis.

The FTSE 100-listed drugmaker said its partner FibroGen China, a subsidiary of FibroGen Inc. received marketing authorisation from the Chinese National Medical Products Administration for orally-administered roxadustat.

READ: AstraZeneca’s Imfinzi cancer drug fails in another late-stage trial

The firm said it will be responsible for bringing the drug to market in the country, while FibroGen will manage the processes of manufacturing, regulation and continued research.

AstraZeneca said it expects to launch roxadustat in China in the second half of 2019.

Sean Bohen, AstraZeneca’s executive vice president, Global Medicines Development and chief medical officer, said: "Roxadustat is a long-awaited, first-in-class medicine for patients with anaemia in chronic kidney disease that are on dialysis.

“This first approval of roxadustat in China is a significant step towards achieving our ambition to transform care in a condition where prevalence in China is increasing."

View full AZN profile View Profile

AstraZeneca Timeline

Related Articles

woman's face
Tue
Here we take a closer look at SkinBioTherapeutics, the life sciences group that is using bacteria to improve people’s skin
man with erectile dysfunction
June 17 2019
Headline results from the trial of MED2005 are due before the end of 2019, while Futura is also confident of hearing back from UK regulators about its pain relief gel later in the year
1557403923_iron.jpg
May 09 2019
Here we take a look under the hood of Shield Therapeutics

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use